CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. The company's deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped it receive breakthrough therapy designation (U.S. Food and Drug Administration), Priority Medicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with primary biliary cholangitis (PBC). The company's evidence-based decision-making and commitment to the highest quality standards reflect its relentless dedication to the people, families and communities it serves.